<DOC>
	<DOCNO>NCT02565368</DOCNO>
	<brief_summary>This study randomize , open-label , single dose , 2-way crossover study compare pharmacokinetic characteristic CKD-395 0.5/1000 mg healthy male volunteer .</brief_summary>
	<brief_title>A Clinical Study Compare Pharmacokinetic Characteristics CKD-395 0.5/1000 mg Healthy Male Volunteers</brief_title>
	<detailed_description>To healthy male subject twenty six ( 26 ) , follow treatment administer dose period feed condition ( high fat meal ) wash-out period minimum 7 day . Treatment A ( Reference Drug ) : DuvieTM Tab . 0.5mg 1T + Glicophage XR Tab . 1000mg 1T Treatment B ( Test Drug ) : CKD-395 0.5/1000mg Tab . 1T Pharmacokinetic blood sample collect 48hrs . Safety pharmacokinetic assess .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Healthy man old 19 year time screen . 2 . BMI 17.5kg/m2 less 30.5kg/m2 weight 55kg 3 . Subject without congenital chronic disease psychotic symptom finding medical examination . 4 . Suitable subject determine laboratory test hematology test , blood chemistry , urinalysis test accord characteristic drug screen test ECG test . 5 . Subject fully understand clinical trial indepth explanation give prior clinical study , decide join clinical trial sign consent form approve Chonbuk National University Hospital IRB . 6 . Subjects able comply schedule visit , laboratory test procedure . 1 . Subjects history blood , kidney , endocrine , respiratory , gastrointestinal , urinary , cardiovascular , hepatic , psychiatric , neurological allergic disease clinically significant ( Except untreated asymptomatic seasonal allergy time administration ) 2 . Subjects history gastrointestinal disease gastrointestinal surgery affect drug absorption . 3 . Subjects show AST AST &gt; 2 time upper limit normal range . 4 . Subjects drink Alcohol &gt; 210g/week within 6 month prior screen . 5 . Subjects take medication involve clinical trial bioequivalence test within three month first dose medication character . 6 . Subjects show Systolic Blood Pressure ≥ 140 mmHg Diastolic Blood Pressure ≥ 90 mmHg screening . 7 . Subjects history alcohol drug abuse , within 1 year 8 . Subjects treat metabolize enzyme inducer inhibitor barbital within 30days prior first dosing . 9 . Smoker ( ≥ 20cigarettes/day ) 10 . Subjects take ETC OTC medicine within 10days first IP administration . 11 . Subjects whole blood donation within two month component blood donation within 1month prior first dosing . 12 . Subjects increase risk due clinical test administration drug Severe grade / chronic medical , mental condition abnormal laboratory result may interfere analysis test result . 13 . Patients hypersensitivity lobeglitazone thiazolidinediones ( Rosiglitazone , Rioglitazone ) Metformin biguanides 14 . Patients severe heart failure congestive heart failure need drug therapy 15 . Patients liver disease 16 . Patients severe renal disease 17 . Patients diabetes mellitus ketoacidosis , diabetes coma prior 18 . Patients surgery , severe infection , severe trauma 19 . Subjects hereditary disease galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption 20 . Patients renal disease renal failure cause cardiovascular collapse , acute myocardial infarction , sepsis ( Serum creatinine ≥ 1.5mg/dL abnormal creatinie clearance ) 21 . Patients test inject radioactive iodine vein 22 . Patients severe infection severe traumatic whole body injuries 23 . Patients undernourishment condition starvation state hyposthenia hypopituitarism , hypoadrenalism 24 . Patients respiratory failure , stomach disease 25 . Subjects able intake high fat meal 26 . Subjects able comply guideline describe protocol . 27 . Subjects determine investigator 's decision unsuitable clinical trial participation .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>